CJC-1295 w/DAC

Fitness & Performance

CJC-1295 w/DAC

A long-acting GHRH analog category product positioned for sustained GH-axis signaling. The DAC modification is commonly used to differentiate it from shorter-acting CJC-1295 formats and from ghrelin-receptor secretagogues.

Common Clinical Application

Commonly positioned by providers who want a longer-acting GHRH analog category within hormone optimization, recovery, and longevity-focused protocols.

Clinical Advantages

• Longer-acting GHRH analog category
• DAC-based extended exposure profile
• Distinct from non-DAC CJC-1295 and secretagogues
• Relevant to GH/IGF-1 pathway positioning
• Useful for advanced GH-axis formulary planning

Clinical Overview

CJC-1295 w/DAC is valuable when clinics want to differentiate duration and pathway. It should be described as an extended-exposure GHRH analog category, not as direct hormone replacement or an outcome-guaranteed performance product.

Quality & Handling

Review product labeling, lot-specific documentation, concentration, storage conditions, and applicable handling procedures upon receipt. Follow internal facility standards and professional protocols for storage, handling, and provider-directed use.

Important: This page is intended for professional product and formulary information only. Nothing contained herein constitutes medical advice, prescribing guidance, or claims regarding diagnosis, treatment, cure, prevention, weight loss, cosmetic change, fertility, performance outcomes, or specific patient results.